-

Agilent Accelerates Digital Pathology with the Launch of the Agilent S540MD Slide Scanner System

Collaboration with Hamamatsu brings next-level speed and scalability to European pathology labs

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the launch of the Agilent S540MD Slide Scanner System, a whole slide imaging (WSI) digital scanner, available for sale in key European markets. The launch reflects Agilent’s continued investment in digital pathology, expanding its portfolio to meet the growing demand for high-throughput solutions in clinical laboratories.

Pathology laboratories worldwide are under increasing pressure to improve diagnostic precision and operational efficiency while managing growing sample volumes and case complexity. As a result, labs require robust, high-speed scanning solutions that integrate seamlessly into existing workflows, as reliance on traditional glass slide workflows alone can slow turnaround times and overall output. Workflow digitization and AI-driven tools have been proven to be key drivers of workflow efficiency and scalability.

Engineered for speed and scalability, the Agilent S540MD offers capacity for up to 540 slides, continuous loading and standard rack compatibility. The scanner features automated scanning modes and AI-assisted tissue detection, enabling high-volume pathology labs to digitize glass slides efficiently and to implement digital and AI-driven workflows. The new scanner is the Agilent-branded version of the Hamamatsu NanoZoomer S540MD Slide Scanner System.

With the introduction of the Agilent S540MD scanner, Agilent enhances its capabilities in digital pathology, enriching its offering from staining to AI decision support and providing laboratories with increased flexibility to select solutions that align with their specific requirements.

Nina Green, vice president and general manager of the clinical diagnostics division at Agilent, said, “The introduction of the Agilent S540MD Slide Scanner System marks an important advancement in our commitment to equip pathology laboratories with advanced digital technologies. This initiative facilitates the acceleration of diagnostic workflows and supports improved patient outcomes.” She went on to say, “Our partnership with Hamamatsu demonstrates Agilent’s ongoing dedication to delivering integrated, fully interoperable solutions to address the evolving needs of clinical laboratories.”

This announcement underscores Agilent’s commitment to advancing digital pathology by enabling laboratories to streamline diagnostic processes, improve operational efficiency, and leverage AI-powered insights. The Agilent S540MD scanner will initially be available as IVD in Germany, France, Belgium, Spain, Austria, Luxembourg, and Italy (IVDR), the UK (MDR2002) and Switzerland (IvDO) with plans to expand into additional European countries and further milestones are scheduled for 2026.

For more information about Agilent’s digital pathology solutions, visit https://www.agilent.com/en/product/digital-pathology.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.95 billion in fiscal year 2025 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.

Contacts

Media Contact:
Christian Colón
Agilent Technologies Inc.
+1 302-867-4117
christian.colon@agilent.com

Agilent Technologies Inc.

NYSE:A
Details
Headquarters: Santa Clara, California, USA
CEO: Padraig McDonnell
Employees: 18000
Organization: PUB

Release Versions
$Cashtags

Contacts

Media Contact:
Christian Colón
Agilent Technologies Inc.
+1 302-867-4117
christian.colon@agilent.com

Social Media Profiles
More News From Agilent Technologies Inc.

Agilent, OpenAI, BCG Collaborate to Accelerate Customer-Focused, AI-Driven Scientific Innovation

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced a collaboration with OpenAI and Boston Consulting Group (BCG) to accelerate the deployment of artificial intelligence (AI) across the company’s products, operations, and customer workflows. “AI is a top priority, and this partnership reflects both our ambition and our execution commitment — to build the enduring capability, operating model, and capacity required to consistently deliver AI‑driven innovation...

Agilent Receives FDA Approval for Expanded Use of PD-L1 IHC 22C3 pharmDx on Dako Omnis in Esophageal Squamous Cell Carcinoma, Triple-Negative Breast Cancer, Cervical Cancer, and Gastric or Gastroesophageal Junction Adenocarcinoma

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved the expanded use of PD-L1 IHC 22C3 pharmDx, Code GE006, for use on the Dako Omnis platform to aid in identifying patients in the United States with esophageal squamous cell carcinoma (ESCC)3, triple-negative breast cancer (TNBC)4, cervical cancer5, and gastric or gastroesophageal junction (GEJ) adenocarcinoma6, who may be eligible for treatment...

Agilent Introduces OpenLab Sync to Support Guided, Digital Execution in the Laboratory

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the introduction of OpenLab Sync, a new Lab Execution System (LES) that enables laboratories to digitally connect scientific workflows from method design through execution at the bench. OpenLab Sync extends Agilent’s OpenLab laboratory informatics portfolio beyond traditional data and sample management, enabling guided, standardized, and traceable execution of laboratory work in regulated environments. As...
Back to Newsroom